Role of MPE in clinical trials - Final Composition
Publication Date: Aug 30th, 2020 10:53, Category: EFOMP Announcements
After a successful call on new Working Group (WG) entitled “Role of MPE in clinical trials” EFOMP is proud to announce, that the final composition was approved according to EFOMP procedures.
The WG is ready to operate under Scientific Committee from September 2020 to September 2022. The chair of the WG is Dr Natalie Abbot (UK) and the vice chair is Christian Rønn Hansen (DK).
The rationale of the WG: To develop a consensus guidance document for the work MPEs do in clinical trials across Europe. The document will complement the work by American colleagues in AAPM TG 113. In addition, the document will aim to complement any MPE guidance from National Member Organisations. Furthermore, the document will aim to cover external beam radiotherapy, brachytherapy, nuclear medicine / molecular radiotherapy and imaging. Including all of these areas should enable the WG to cover all current and emerging areas of the role of an MPE in clinical trials. Considerations will be made for the ethics of MPEs working in clinical trials. This will include, but is not limited to, general advice and appropriate use of anonymized data.
EFOMP_Clinical_Trials_WG_composition_announcement.pdf Size: 146,29 KB